Nonarteritic anterior ischemic optic neuropathy (NAION) is one of the leading causes of sudden and irreversible loss of vision in older adults. In a prospective randomized trial of 60 patients with NAION, investigators have shown that the addition of the corticosteroid fluocortolone (FC) to standard therapy significantly improves both short- and long-term visual acuity, especially when given soon after the onset of symptoms. Their results are published in Restorative Neurology and Neuroscience.
NAION, a disabling condition which can affect both eyes in up to 19% of cases within 5 years, occurs in about 2.3 per 100,000 adults over the age of 50. Incidence increases steadily with age. Patients have few well-tested or effective treatment options beyond the standard administration of pentoxifylline (PTX), which is thought to improve visual acuity by improving the microcirculation in oxygen-deprived optic nerve tissue. No current treatment reverses or limits the course of the disease. The goal of the current study was to see whether adding a steroid to PTX could improve vision, perhaps by reducing edema or inflammation.
Researchers from the Institute of Experimental Ophthalmology, University of Münster, Germany, studied 55 patients diagnosed with NAION who had developed sudden loss of visual acuity less than 3 days before the initial consultation. These patients were treated with PFX as well as adjunctive therapy with FC during the first 2-3 months (which was gradually tapered). The control group received only PFX.
Investigators found that PFX alone had no significant beneficial effects on either visual acuity (as measured as Best Corrected Visual Acuity, BCVA) or visual field after 3 days and 6 months of treatment. However, adding FC significantly boosted outcomes: those receiving FC were more likely to experience improvement and less likely to have worsened visual acuity. Progress was even more pronounced after 6 months of therapy. More than two thirds of NAION patients treated with the combination therapy had better long-term vision compared to only 14% of those only treated with PFX.
The authors explain why FC apparently benefits those who have less severe visual loss. “NAION is caused by ischemia of the optic nerve head…. This restriction of blood supply, depending upon its degree, results in primary irreversible loss of retinal ganglion cells (RGC) and secondary delayed RGC loss related to subsequent optic-disc edema,” says Verena Prokosch, PhD, Dr. med., Institute of Experimental Ophthalmology.
“Corticosteroids do not appear to reduce primary cell death, explaining the lack of benefit of FC therapy in patients with a BCVA score worse than 0.05. This may not be the case for patients with moderate BCVA loss who suffer secondary RGC loss due to optic-nerve swelling, revealing a possible therapeutic window for FC,” explains co-author Solon Thanos, MD, Prof. Dr. med. Dr. rer.nat., Institute of Experimental Ophthalmology. Prof. Dr. Thanos suggests that the pronounced long-term effect of FC on visual acuity found in the study could be attributed to early and prolonged treatment at a dose higher than previously tested.
# # #
NOTES FOR EDITORS
“Visual outcome of patients following NAION after treatment with adjunctive fluocortolone,” by Verena Prokosch, Solon Thanos. Restorative Neurology and Neuroscience, 2013.DOI 10.3233/RNN-120292. Published by IOS Press online ahead of issue.
Full text of the article is available to credentialed journalists upon request. Contact Daphne Watrin, IOS Press at +31 20 688 3355 or [email protected]. Journalists wishing to interview the authors should contact the Institute of Experimental Ophthalmology at + 492518356915 or [email protected].
ABOUT RESTORATIVE NEUROLOGY AND NEUROSCIENCE (RNN)
An interdisciplinary journal under the editorial leadership of Bernhard Sabel, PhD, Restorative Neurology and Neuroscience publishes papers relating the plasticity and response of the nervous system to accidental or experimental injuries and their interventions, transplantation, neurodegenerative disorders and experimental strategies to improve regeneration or functional recovery and rehabilitation. Experimental and clinical research papers adopting fresh conceptual approaches are encouraged. The overriding criteria for publication are novelty, significant experimental or clinical relevance and interest to a multidisciplinary audience.
RNN Editorial Office
Prof. Dr. Bernhard Sabel
Institut für Medizinische Psychologie
Otto-v.-Guericke Universität Magdeburg
Email: [email protected]
ABOUT IOS PRESS
Commencing its publishing activities in 1987, IOS Press serves the information needs of scientific and medical communities worldwide. IOS Press now (co-)publishes over 100 international journals and about 120 book titles each year on subjects ranging from computer sciences and mathematics to medicine and the natural sciences.
IOS Press continues its rapid growth, embracing new technologies for the timely dissemination of information. All journals are available electronically and an e-book platform was launched in 2005.
Headquartered in Amsterdam with satellite offices in the USA, Germany, India and China, IOS Press has established several strategic co-publishing initiatives. Notable acquisitions included Delft University Press in 2005 and Millpress Science Publishers in 2008.